Core Viewpoint - Zhongmu Co., Ltd. has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Virus Disease, marking a significant advancement in the company's product offerings [1] Group 1 - The vaccine is identified as HuN-1/2017 strain and is produced through suspension culture [1] - The company has been issued a New Veterinary Drug Registration Certificate, which is a crucial step for commercialization [1]

Core Viewpoint - Zhongmu Co., Ltd. has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Virus Disease (HuN-1/2017 strain) as a new veterinary drug [1] Group 1 - The vaccine has been developed in accordance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The approval includes the issuance of a "New Veterinary Drug Registration Certificate" for the product [1]

Core Viewpoint - The company, Keqian Bio (688526.SH), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine for Seneca virus A (HB16 strain) as a new veterinary drug [1] Group 1: Company Developments - Keqian Bio has been granted a new veterinary drug registration certificate for its inactivated vaccine targeting Seneca virus A, which is significant for the company's product portfolio [1] - The approval aligns with the regulations set forth in the Veterinary Drug Administration Regulations and the Veterinary Drug Registration Measures [1] Group 2: Industry Context - Seneca virus disease, caused by Seneca virus A, primarily affects pigs and is characterized by lesions that can be confused with other diseases such as foot-and-mouth disease and vesicular stomatitis [1] - The disease has been reported in countries like Canada, Brazil, and the United States, indicating its prevalence and the potential market need for effective vaccines [1]

Core Viewpoint - The company, Keqian Bio (688526.SH), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Seneca virus disease in pigs, marking a significant advancement in veterinary medicine [1] Group 1: Company Developments - Keqian Bio has been granted a new veterinary drug registration certificate for its inactivated vaccine (HB16 strain, suspension culture) [1] - The approval is in accordance with the Veterinary Drug Administration Regulations and the Veterinary Drug Registration Measures [1] Group 2: Industry Context - Seneca virus disease, caused by Seneca virus A (SVA), is a viral infectious disease primarily affecting pigs, characterized by lesions similar to foot-and-mouth disease and other diseases [1] - The disease is transmitted mainly through contact and has been reported in countries such as Canada, Brazil, and the United States [1]